Using Patient-Derived Organoids to Prioritise ADC Clinical Development & Derisk Early Toxicities
- Exploring how HUB Organoid Technology allows for the development of patient-derived organoids with high fidelity to the original tumour
- Using HUB Organoids to derisk the preclinical ADC development, prioritise indications, uncover off-target toxicities, and complement your biomarker strategy
- Assessing how the next frontier for ADC organoids will see MoA studies being performed to optimise clinical candidates and patient selection